Cover Image

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial

Saved in:
Bibliographic Details
Main Authors: Fosså, Alexander (Author) , Molin, Daniel (Author) , Bröckelmann, Paul J. (Author) , Schneider, Gundolf (Author) , Schnetzke, Ulf (Author) , Linderoth, Johan (Author) , Kamper, Peter M. H. (Author) , Leppä, Sirpa M. (Author) , Meißner, Julia (Author) , Schaub, Valdete (Author) , Lia, Kjersti (Author) , Fuchs, Michael (Author) , Borchmann, Peter (Author) , Böll, Boris (Author)
Format: Article (Journal) Editorial
Language:English
Published: March 2025
In: HemaSphere
Year: 2025, Volume: 9, Issue: 3, Pages: 1-5
ISSN:2572-9241
DOI:10.1002/hem3.70099
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hem3.70099
Get full text
Author Notes:Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Johan Linderoth, Peter M.H. Kamper, Sirpa M. Leppä, Julia Meissner, Valdete Schaub, Kjersti Lia, Michael Fuchs, Peter Borchmann, Boris Böll
Description
Item Description:Gesehen am 25.02.2026
Physical Description:Online Resource
ISSN:2572-9241
DOI:10.1002/hem3.70099

Similar Items